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Cellular metabolism(HPV) E7 oncoprotein shares functional similarities with such proteins as
adenovirus E1A and SV40 large tumor antigen. As one of only two viral proteins always expressed in HPV-
associated cancers, E7 plays a central role in both the viral life cycle and carcinogenic transformation. In the
HPV viral life cycle, E7 disrupts the intimate association between cellular differentiation and proliferation in
normal epithelium, allowing for viral replication in cells that would no longer be in the dividing population.
This function is directly reﬂected in the transforming activities of E7, including tumor initiation and induction
of genomic instability.
© 2008 Elsevier Inc. All rights reserved.Introduction
Human papillomaviruses (HPVs) are a DNA virus family of
approximately 200 types that display a marked tropism for squamous
epithelium. Despite a similar genomic make-up, different HPVs infect
epithelia at distinct anatomic locations. Approximately 30 HPV types
infect the anogenital and oral mucosa and can be further classiﬁed as
“low-risk” and “high-risk” based on the clinical prognosis of their
associated lesions. Low-risk HPVs cause benign epithelial hyperplasias
(warts), while high-risk HPVs cause lesions that have a propensity for
malignant progression. Virtually all cervical carcinoma cases are
associated with high-risk HPV infection, and two viral proteins, E6 and
E7, which are consistently expressed in the tumors, are required for
both the induction and maintenance of the transformed phenotype
(Munger et al., 2004).
Cellular transformation activities of HPV E7 proteins
In the mid 1980s it was recognized that high-risk HPV genomes
encode cellular transformation activities when assayed in rodent
ﬁbroblast lines such as NIH3T3 cells (Yasumoto et al., 1986) or in the
classical ras oncogene cooperation assay in baby rat kidney cells.E. McLaughlin-Drubin),
l rights reserved.(Matlashewski et al., 1987). Subsequent mutational analyses revealed
that the E7 protein scored as the major transforming activity of high-
risk HPVs in these assay systems (Bedell et al., 1989; Kanda et al., 1988;
Phelps et al., 1988; Tanaka et al., 1989; Vousden et al., 1988; Watanabe
and Yoshiike, 1988; Yutsudo et al., 1988).
Later studies revealed that expression of cloned high-risk HPV
genomes in the natural host cell type of HPVs, primary human genital
epithelial cells, causes life span extension and cellular immortalization
and inhibits keratinocyte differentiation and facilitates immortaliza-
tion (Schlegel et al., 1988; Woodworth et al., 1988, 1989). High-risk
HPV genome expressing keratinocytes grown in organotypic raft
cultures display cellular alterations and abnormalities in tissue
architecture that resemble high-grade HPV-associated clinical lesions
(McCance et al., 1988; Woodworth et al., 1990). The resulting cell lines
were non-tumorigenic in nude mice but tumorigenic clones were
obtained when cultured over extended periods of time or when
additional oncogenes such the ras or fos oncogenes were co-expressed
(DiPaolo et al., 1989; Durst et al., 1989; Hurlin et al., 1991; Pei et al.,
1993). Mutational analyses revealed that the E7 protein in cooperation
with E6 is necessary for these transforming activities in human
epithelial cells (Bedell et al., 1989; Hawley-Nelson et al., 1989; Hudson
et al., 1990; Munger et al., 1989a). The transforming activities of HPV
E7 proteins correlate with the low-risk/high-risk classiﬁcation, as low-
risk HPV E7 proteins, such as HPV6 and 11 E7, have greatly decreased
transforming and immortalizing activities as compared to high-risk
HPV E7 proteins (Barbosa et al., 1991; Halbert et al., 1992).
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The E7 proteins are small, acidic polypeptides composed of
approximately 100 amino acids (Fig. 1). The amino terminus of E7
contains a region of sequence similarity to a portion of conserved
region (CR) 1 and the entire CR2 of adenovirus (Ad) E1A and related
sequences in simian vacuolating virus 40 (SV40) large tumor antigen
(T Ag) (Figge et al., 1988; Phelps et al., 1988; Vousden and Jat, 1989). As
with SV40 T Ag and Ad E1A, these two conserved regions signiﬁcantly
contribute to the transforming activities of high-risk HPV E7
oncoproteins (Edmonds and Vousden, 1989; Jewers et al., 1992;
Phelps et al., 1992; Storey et al., 1990; Watanabe et al., 1990). A
conserved Leu-X-Cys-X-Glu (LXCXE) motif in the CR2 homology
domain is necessary and sufﬁcient for the association of E7 protein
with the retinoblastoma tumor suppressor protein, pRB (Munger et al.,
1989b). Some studies claim that the C-terminal E7 domain contains an
independent, low-afﬁnity pRB binding site (Liu et al., 2006; Patrick et
al., 1994), but HPV16 E7 mutants with a deletion of the pRB core
binding site in CR2 fail to associate with pRB family members as
determined by Western blotting and extensive proteomic analyses of
associated cellular protein complexes (K.W. Huh, M. Grace, C. L.
Nguyen and K. Munger, unpublished data). Adjacent to the LXCXE
motif is a consensus casein kinase II (CK II) phosphorylation site
(Barbosa et al., 1990; Firzlaff et al., 1989). The carboxyl terminus is
phosphorylated by an as yet unidentiﬁed kinase (Massimi and Banks,
2000) and importantly contributes the transforming activities of E7
(Helt et al., 2002; Helt and Galloway, 2001). The E7 carboxyl terminus
contains a zinc-binding domain that is composed of two Cys-X-X-Cys
motifs (Barbosa et al., 1989) and functions as a dimerization domain
(Clemens et al., 1995; Liu et al., 2006; McIntyre et al., 1993;
Ohlenschlager et al., 2006), although there is no compelling evidence
that E7 exists as a dimer in vivo and/or that dimerization is necessary
for the biological activities of E7. Interestingly, HPV E6 proteins consist
of two tandem copies of a Cys-X-X-Cys motif that shares sequence
similarity to the E7 carboxyl terminus, indicating that E6 and E7 may
have a common ancestral precursor (Cole and Danos, 1987). The 3-
dimensional structure of HPV E7 proteins has been solved by NMR (Liu
et al., 2006) and X-ray crystallography (Ohlenschlager et al., 2006).Fig. 1. Schematic representation of the HPV E7 oncoprotein and affected cellular processes.
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(Fig. 1).
HPV16 E7 migrates on SDS polyacrylamide gels with an apparent
molecular size of 18 to 20 kDa, rather than according to its predicted
molecular weight of ∼11 kDa (Smotkin and Wettstein, 1986, 1987);
this aberrant migration is mediated by the amino terminal CR1
homology domain (Heck et al., 1992; Münger et al., 1991) and may be
caused by the high content of acidic residues (Armstrong and Roman,
1993). HPV16 E7 is located largely in the cytoplasm (Huh et al., 2005;
Nguyen et al., 2007; Ressler et al., 2007; Smotkin andWettstein, 1987)
but also exists in nuclear pools (Greenﬁeld et al., 1991; Sato et al.,
1989; Smith-McCune et al., 1999). Although HPV16 E7 does not have a
prototypical nuclear targeting sequence, it is actively transported into
the nucleus through a novel Ran-dependent that does not involve Kap
β import receptors (Angeline et al., 2003). More recent studies have
shown that E7 also contains a nuclear export sequence and can shuttle
between the cytoplasm and nucleus (Knapp et al., in press). In addition
to nuclear and cytoplasmic pools of E7, nucleolar HPV16 E7
localization has also been reported (Zatsepina et al., 1997), but in
most immunoﬂuorescence studies nuclear HPV16 E7 staining seems
to speciﬁcally exclude nucleolar structures. The half-life of HPV16 E7 is
less than 2 h (Smotkin and Wettstein, 1987). E7 is degraded via a
ubiquitin-mediated proteasomal mechanism that involves conjuga-
tion of ubiquitin to the amino terminus of E7 (Reinstein et al., 2000). A
cullin 1 containing ubiquitin ligase complex has been implicated in
HPV16 E7 degradation (Oh et al., 2004a) although association of
HPV16 E7 with cullin 1 was not detected in other studies (Huh et al.,
2007).
Glycerol gradient centrifugation experiments demonstrated that
HPV16 E7 is a component of higher molecular weight complexes,
indicating that it may associate with cellular protein complexes
(Smotkin and Wettstein, 1987). E7 lacks intrinsic enzymatic activities
and speciﬁc DNA binding activities and it is now widely accepted
that its biological activities are linked to its ability to associate with
and subvert the normal activities of cellular regulatory complexes
(Fig. 1).The unstructured amino terminal 37 amino acid residues of HPV16 E7 have sequence
entical and chemically similar amino acid residues indicated by red and blue boxes,
but do not directly contribute to pRB binding. The core pRB binding site (LXCXE), also
osphorylation site (CKII). The carboxyl terminal E7 domain shown here is fromHPV45 E7
quence has a compact β1β2α β3α2 topology that represents a unique zinc-binding fold.
wo Cys-X-X-Cys motifs separated by 29 amino acid residues. Cellular processes affected
references.
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During carcinogenic progression the HPV genome frequently
integrates into a host cell chromosome and, as a result, the viral
oncoproteins, E6 and E7, are the only viral proteins that are
consistently expressed in HPV positive cervical carcinomas. Viral
genome integration is a terminal event and is thus not a manifestation
of the normal viral life cycle. Hence, the oncogenic activities of high-
risk HPV E7 proteins reﬂect their functions during the viral life cycle.
The HPV life cycle is intimately associated with the differentiation
process of the infected epithelial cell. The skin is the largest organ of
the human body and is subject to continuous turnover. It contains a
single layer of dividing cells, the basal cells. Basal cells undergo
asymmetric mitosis; one daughter cell remains an undifferentiated,
proliferating basal cell whereas the other daughter becomes a
differentiating suprabasal cell. The suprabasal daughter cell with-
draws from the cell division cycle and undergoes a program of
terminal differentiation. This ensures the mechanical stability of the
skin and provides protection for the dividing basal cells from direct
exposure to environmental mutagens. In order to establish a
persistent infection, papillomaviruses need to infect basal cells
where the viral genomes are maintained at a low copy number. The
production of infectious progeny virus, however, exclusively occurs in
the terminally differentiated layers of the epithelium (reviewed in Lee
and Laimins, 2007).
With the exception of the E1/E2 complex, papillomaviruses lack
essential enzymes for viral genome replication; the host cell's DNA
synthesis machinery must be utilized for this purpose (reviewed in
Stubenrauch and Laimins, 1999). In normal epithelia, cellular DNA
synthesis no longer occurs in differentiated epithelial cells, making
them inherently incapable of supporting HPV replication. Conse-
quently, papillomaviruses need to uncouple the processes of cellular
differentiation and proliferation. The strategies that some HPVs have
developed to achieve this contribute to their transforming activities.
Infected cells leaving the basal layer remain competent to support
DNA synthesis largely due to the actions of the E7 protein (Cheng et al.,
1995). There appear to be HPV type-speciﬁc differences with regard to
the speciﬁc roles that E7 proteins play in the viral life cycle, as HPV11
and 31 E7 are where shown to be required for episomal maintenance
of the viral genome (Oh et al., 2004b; Thomas et al., 1999), whereas
HPV16 and 18 E7 are necessary for the productive stage of the viral life
cycle (Flores et al., 2000; McLaughlin-Drubin et al., 2005). While many
of the biological activities of E7 that are necessary for the viral life
cycle remain to be elucidated, it has been shown that the ability of
HPV16 E7 to allow suprabasal cells to support DNA synthesis is linked
to E7's ability to bind pRB family members but not with its ability to
induce their degradation (Collins et al., 2005). On the other hand, the
capacity of HPV16 E7 to perturb differentiation correlates with both
E7's binding to and degradation of pRB family members, suggesting
that different key stages of the productive stage of the HPV16 life cycle
rely on different functions of E7 (Collins et al., 2005).
Activation of E2F-dependent transcription through degradation of
the retinoblastoma tumor suppressor protein, pRB
HPV E7 proteins associate with pRB and the related pocket
proteins, p107 and p130, via the LXCXE motif in CR2 (Dyson et al.,
1992; Munger et al., 1989b). The best-studied function of the pocket
proteins is the ability to regulate G1/S entry and progression by
modulating the transcriptional activities of E2F transcription factors
(reviewed in Frolov and Dyson, 2004). E2F transcription factors are
heterodimers that contain an E2F (E2F1-8) and a DP (DP-1, DP-2)
subunit and are critical regulators of G1 exit and S-phase progression.
In addition, a number of other cellular processes, including cellular
differentiation, apoptosis, and genomic instability, are controlled by
E2Fs (reviewed in Dyson, 1998). The G1 speciﬁc pRB/E2F complex actsa transcriptional repressor. In normal cells, disruption of the pRB/E2F
repressor complex is triggered by cdk4/6 and cdk2 mediated pRB
phosphorylation in late G1; the dissociated E2F acts as a transcrip-
tional activator of genes necessary for S-phase entry and progression.
Like SV40 T Ag, high-risk HPV E7 preferentially associates with G1-
speciﬁc, E2F-bound pRB (Dyson et al., 1992). This causes disruption of
pRB/E2F repressor complexes and, thus, uncontrolled G1 exit and S-
phase entry. In addition to the LXCXE motif in CR2, carboxyl terminal
E7 sequences are necessary for disruption of pRB/E2F complexes
(Huang et al., 1993; Wu et al., 1993).
However, unlike SV40 T Ag and Ad E1A, which inactivate pRB/E2F
complexes by stoichiometric pRB association, high-risk HPV E7
proteins destabilize pRB through proteasomal degradation (Boyer et
al., 1996; Jones et al., 1997b) via a mechanism that involves association
with and reprogramming of the cullin 2 ubiquitin ligase complex by
HPV16 E7 (Huh et al., 2007). The induction of the aberrant pRB
degradation by high-risk HPV E7 proteins and the resulting activation
of E2F-mediated transcription represent important mechanisms by
which these viruses achieve and maintain S-phase competence in
differentiated epithelial cells. In addition to the core pRB binding site
in CR2, sequences in the CR1 homology domain are necessary for pRB
degradation and mutational studies suggest that the ability of high-
risk HPV E7 proteins to destabilize pRB family members is necessary
for cellular transformation (Jones et al., 1997b).
Low-risk HPV E7 proteins bind pRB with lower efﬁciency
(approximately 10-fold lower) than the high-risk HPV E7 proteins
(Gage et al., 1990; Munger et al., 1989b). This difference in pRB binding
efﬁciency maps to a single amino acid (Asp 21 in HPV16 E7 versus Gly
22 in HPV6 E7) and substitution experiments indicated that this single
amino acid residue was the primary determinant for pRB-binding
afﬁnity and transformation capacity of the mucosal HPV E7 proteins
(Heck et al., 1992; Sang and Barbosa, 1992). Interestingly, for
cutaneous HPV E7 proteins, the presence of an aspartate residue and
efﬁcient pRB binding is not associated with a high-risk clinical
classiﬁcation in vivo and does not predict transforming potential in
vitro (Ciccolini et al., 1994).
HPV16 E7 can directly bind E2F1 and enhance E2F1-mediated
transcription (Hwang et al., 2002). E2F1 plays a role in mediating the
transcriptional control of the E2F6 gene, which is upregulated at the
G1/S-phase transition to exert an opposing effect on the activities of
E2F-responsive promoters, thereby directing appropriate cell cycle
exit and differentiation (Lyons et al., 2006). Interestingly, HPV E7
associates with E2F6 and abrogates its ability to function as a
transcriptional repressor (McLaughlin-Drubin et al., 2008), suggesting
that the functional deregulation of E2F6 by HPV E7 is needed to
counterbalance the up-regulation of E2F6 as a consequence of the
activation of E2F1 by E7, thus ensuring that the cells remain in an S-
phase-competent state that is necessary for the viral life cycle.
Moreover, given E2F6's possible role in maintaining quiescence
(Ogawa et al., 2002), it is conceivable that the deregulation of E2F6
by HPV E7 aids in allowing HPVs to bypass negative growth signals,
thus allowing cells to exit from G0.
Other mechanisms of G1/S cell checkpoint dysregulation
In addition to targeting pRB for proteasomal degradation, high-risk
HPV E7 proteins also contribute to cell cycle dysregulation through
several additional mechanisms.
Cyclin dependent kinases (cdks) are the motors that drive the cell
division cycle. Multiple mechanisms, most importantly association
with positive regulatory subunits, cyclins, and negative regulators,
cyclin-dependent kinase inhibitors (CKIs), regulate their activity.
Expression of cyclins E and A, the regulatory subunits of cdk2,
which drive S-phase entry and progression, is under E2F control and
they are both expressed at higher levels in E7 expressing cells (Zerfass
et al., 1995).
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growth-inhibitory activities of the CKIs p21CIP1 (Funk et al., 1997; Jones
et al., 1997a) and p27KIP1 (Zerfass-Thome et al., 1996), which are
induced by anti-proliferative signals, including growth factor with-
drawal (Firpo et al., 1994), activation of p53 (el-Deiry et al., 1993), and
loss of cellular adhesion (Assoian, 1997; Fang et al., 1996). Interest-
ingly, p21CIP1 has been implicated in coupling cell cycle arrest and
differentiation in keratinocytes (Alani et al., 1998; Di Cunto et al., 1998;
Missero et al., 1996). The steady state levels of p21CIP1 increase during
differentiation, subsequently inhibiting cdk2 activity and inducing a
G1 growth arrest; interestingly, p21CIP1 levels are increased further
through a non-transcriptional mechanism in the presence of HPV E7.
Although HPV16 E7 expression increases p21CIP1 levels through
protein stabilization (Jian et al., 1998; Jones et al., 1999; Noya et al.,
2001), cdk2 remains active in HPV E7-expressing cells (Funk et al.,
1997; Jones et al., 1997a; Ruesch and Laimins,1997). The ability of HPV
E7 to abrogate CKIs, together with its ability to disrupt pRB/E2F
complexes, which results in increased cyclin E and cyclin A levels,
retains differentiating keratinocytes in a DNA synthesis competent
state. HPV16 E7 can also directly associate with cdk2/cyclin A and
cyclin E complexes (He et al., 2003; Nguyen and Munger, 2008;
Tommasino et al., 1993) resulting in increased cdk2 activity as
measured on a pRB-derived substrate (He et al., 2003).
HPV16 E7 and epigenetic reprogramming
In addition to a DP1/2 containing repressive complex, E2F6 is also a
component of polycomb group (PcG) transcription factor complexes.
Mammalian PcG complexes act as transcriptional repressors, some of
which contain histone methyltransferases (Attwooll et al., 2005;
Ogawa et al., 2002; Trimarchi et al., 2001). Given that in addition to
DP1 and DP2 we also identiﬁed the polycomb group proteins Ring1,
Bmi1, Mel18, hpc2, and L3MBTL2 as HPV16 E7 associated proteins by
tandem afﬁnity puriﬁcation (McLaughlin-Drubin et al., 2008), we
presume that HPV16 E7 associates with both E2F6/DP and E2F/PcG
complexes. This is supported by the ﬁnding that some E2F6 speciﬁc
cellular genes are upregulated, and that E2F6 containing polycomb
bodies are detected at lower levels in E7 expressing cells (McLaughlin-
Drubin et al., 2008).
In addition, E7 interacts with class I histone deacetylases (HDACs)
(Brehm et al., 1999; Longworth and Laimins, 2004), which function as
transcriptional co repressors by inducing chromatin remodeling by
reversing acetyl modiﬁcations of lysine residues on histones. The
association between E7 and HDACs results in increased levels of E2F2-
mediated transcription in differentiating cells (Longworth et al., 2005),
possibly inﬂuencing S-phase progression. Moreover, E7 can also
associate, directly or indirectly, with histone acetyl transferases
(HATs) including p300, pCAF, and SRC1 (Avvakumov et al., 2003;
Baldwin et al., 2006; Bernat et al., 2003; Huang and McCance, 2002)
and has been shown to abrogate SRC1 associatedHATactivity (Baldwin
et al., 2006).
Subversion of p53 functions by HPV E7
The levels and half-life of p53 are increased in E7 expressing cells,
indicating that E7 may perturb p53 degradation (Demers et al., 1994;
Jones et al.,1997a,1997b). Although themechanism of p53 stabilization
in E7 expressing cells is unclear, it is known that it is independent of
p14ARF, an inhibitor of mdm2-mediated p53 degradation (Bates et al.,
1998; Zhang et al., 1998). Nevertheless, normal mdm2 mediated p53
turnover is defective in high-risk HPV E6/E7 expressing cervical
carcinoma cells lines (Hengstermann et al., 2001), and the p53-speciﬁc
ubiquitin ligasemdm2 isnot as efﬁciently bound top53 inE7expressing
cells as compared to normal cells (Seavey et al., 1999). This is intriguing,
as mdm2 has been implicated in the degradation of pRB (Uchida et al.,
2005), and there is a correlation between E7mediated pRB degradationand p53 stabilization (Jones et al., 1997b). Despite the high levels of p53
in E7 expressing cells, the transcriptional activity of p53 is not activated
(Jones et al., 1999), in fact, E7 has been shown to inhibit p53 trans-
criptional activity in reporter assays (Eichten et al., 2002).
Moreover, HPV16 E7 interferes with p53-mediated G1 growth
arrest signaling in response to DNA damage (Demers et al., 1994;
Hickman et al., 1994; Slebos et al., 1994; Vousden et al., 1993). The
mechanistic details of this are unclear but may include aberrant
expression of E2F transcriptional targets (Hickman et al., 1994; Katich
et al., 2001), inactivation of the p53-responsive CKI p21CIP1 (Funk et al.,
1997; Jones et al., 1997a), and destabilization of pRB (Jones et al.,
1997b).
HPV E7 and cell death signaling
Primary human ﬁbroblasts expressing HPV16 E7 are predisposed
to apoptosis, especially under conditions of growth factor deprivation
or when the cells reach conﬂuence. This has been observed with other
viral and cellular oncogenes (Evan et al., 1992; White et al., 1991) and
is sometimes referred to as the “trophic sentinel response”. The
trophic sentinel response represents a cell intrinsic tumor suppressive
pathway that is triggered when the oncogenic aberrant proliferative
signal is in conﬂict with a growth-inhibitory signal generated by a lack
of mitogenic stimulation. Generation of this signal in E7 expressing
ﬁbroblasts requires integrity of the p53 tumor suppressor pathway,
but does not involve increased expression of p53-responsive genes
(Eichten et al., 2004). While it is accompanied by caspase activation,
the HPV16 E7 induced trophic sentinel response still occurs when
caspases are inhibited and hence represents a form of cell death that is
distinct from apoptosis. Recent experiments with normal human
keratinocytes have revealed that HPV16 E7 expression may cause
metabolic stress that causes activation of an autophagy-like process
(Zhou and Münger, submitted).
Anoikis, a form of apoptosis, is triggered when cells attempt to
enter S-phase despite a lack of matrix attachment (Frisch and
Screaton, 2001). The resistance to anoikis is a hallmark of cellular
transformation and is characterized by the ability of transformed cells
to form foci and display anchorage independent growth. High- and
low-risk, as well as BPV1 E7, associate with the 600 kD retinoblastoma
protein-associated factor, p600 (DeMasi et al., 2005; Huh et al., 2005).
Although the biological functions of p600 have not been fully
elucidated in mammalian cells, reports on p600 homologs in Droso-
phila and Arabidopsis suggest that p600 may play a role in
chromosome segregation (Sekelsky et al., 1999), synaptic transmission
at the neuromuscular junction (Richards et al., 1996), calcium inﬂux
(Xu et al., 1998), and/or polar auxin transport (Gil et al., 2001). A recent
study identiﬁed p600 as a novel microtubule-associated protein
(MAP) that is developmentally regulated in neurons (Shim et al.,
2008). The p600 protein contains a RING ﬁnger/UBR domain and
functions as a ubiquitin ligase in the N-end rule pathway (Tasaki et al.,
2005) that is involved in the ubiquitination of proteins through an
interaction with their N-terminus (reviewed in Mogk et al., 2007).
Experiments involving RNAi knockdown of p600 in mammalian cells
have implicated p600 in anoikis (DeMasi et al., 2007; Huh et al., 2005).
Therefore, the interaction between E7 and p600 may deregulate
anoikis and protect detached cells from apoptosis, thereby contribut-
ing to viral transformation (DeMasi et al., 2007; Huh et al., 2005),
Consistent with this idea, HPV16 E7 associates with p600 through the
CR1 domain, which, is necessary for the transformation capability of
HPV16 E7 (Edmonds and Vousden,1989; Gulliver et al., 1997; Phelps et
al., 1992), as well as BPV1 E7 (DeMasi et al., 2005).
Modulation of cytostatic cytokine signaling by HPV E7
Transforming growth factor β (TGF-β) is potent inhibitor of
epithelial cell growth, and acquisition of TGF-β resistance is a
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cervical carcinoma cell lines are TGF-β resistant (De Geest et al., 1994),
and ectopic HPV16 E7 expression abrogates TGF-β mediated growth
inhibition (Pietenpol et al., 1990). Both p21CIP1 and p27KIP1 have been
implicated in TGF-β mediated growth inhibition (Datto et al., 1995;
Elbendary et al., 1994; Polyak et al., 1994); and HPV16 E7's ability to
inactivate these CKIs may contribute to its ability to abrogate TGF-β
mediated growth inhibition. TGF-β also induces a cdk4/cdk6 speciﬁc
CKI, p15INKB (Hannon and Beach, 1994) and p15INKB-induced growth
suppression may require functional pRB, which is targeted fro
degradation by HPV16 E7.
However, acquisition of TGF-β resistance in HPV positive cell line is
a multi-step process. TGF-β treatment leads to decreased expression
of the HPV E6 and E7 oncoproteins; consequently, freshly derived
HPV-containing epithelial cell lines remain sensitive to TGF-β (Creek
et al., 1995; Woodworth et al., 1990). This effect is mediated by a
mechanism that involves the ski oncogene and NFI sites in the viral
upstream regulatory region (URR) and acquisition of TGF-β resistance
involves this complex (Baldwin et al., 2004).
HPV positive cervical carcinoma cell lines also acquire resistance to
tumor necrosis factorα (TNF) (Villa et al., 1992), an important immune
response mediator that is produced by cytotoxic T cells in response to
a viral infection. Normal keratinocytes undergo G1 growth arrest and
cellular differentiation in response to TNF (Basile et al., 2001) through
NF-kB-mediated induction of p21CIP1 (Basile et al., 2003). TNF-related
cytokines such as Fas ligand and TNF-related apoptosis inducing
ligand (TRAIL) do not affect keratinocyte proliferation (Basile et al.,
2001). In contrast, HPV16 E7-expressing keratinocytes continue to
proliferate in the presence of TNF (Vieira et al., 1996; Villa et al., 1992).
TNF triggers apoptosis when co-administered with the protein
synthesis inhibitor cycloheximide, and HPV E7 expressing keratino-
cytes exhibit increased apoptosis upon TNF/cycloheximide treatment
(Basile et al., 2001; Stoppler et al., 1998).
HPV E7 also compromises interferon (IFN) signaling through
associationwith and inhibition of IFN-α induced nuclear translocation
of p48, the DNA binding component of ISGF-3 (Barnard and McMillan,
1999; Barnard et al., 2000). Interferon expression is activated by
interferon regulatory factors (IRFs) and HPV16 E7 can associate with
IRF-1 and impair its transcriptional activity (Park et al., 2000; Perea et
al., 2000). Moreover, IFN-γ has been shown to inhibit HPV16 E7
expression, and IFN-γ-induced suppressor of cytokine signaling-1
(SOCS-1)/JAB can associate with and induce ubiquitin-mediated
degradation of E7 (Kamio et al., 2004).
HPV16 E7 may also interfere with insulin-like growth factor (IGF)
signaling, which regulates cell survival. HPV16 E7 has been reported to
associate with insulin-like growth factor binding protein-3 (IGFBP-3)
(Mannhardt et al., 2000) and accelerate its proteasome-mediated
degradation (Santer et al., 2007). HPV16 E7 expressing cells express
increased IGFBP-2 and IGFBP-5 levels through an NF-kB dependent
mechanism, speciﬁcally under conditions of growth factor depletion
(Eichten et al., 2004).
Effects of HPV E7 on cellular metabolism
The metabolism of cancer cells is based on energy generation
through glycolytic processes rather than mitochondrial respiration
(reviewed in Aisenberg,1961;Warburg, 1936). HPV16 E7 can associate
with and alter the activity of the metabolic enzyme pyruvate kinase
(PK) (Zwerschke et al., 1999). Presumably as a consequence of this
association, HPV16 E7 transformed cells contain high levels of a
relatively inactive, dimeric form of PK and such cells derive their
metabolic energy mostly from glycolytic processes rather than from
oxidative phosphorylation (Mazurek et al., 2001).
HPV16 E7 has also been found to associate with and allosterically
activateα-glucosidase (Zwerschke et al., 2000). This enzyme regulates
glycogen catabolism and similar to many other tumor types, HPV-associated cervical cancers contain relatively low glycogen levels
(Pedersen, 1975).
Transformed cells often have a higher pH and HPV E7 expression
in NIH 3T3 cells causes intracellular alkalinization potentially due to
increased activity of the Na+/H+ exchanger protein. Inhibition of this
process decreased cell proliferation and inhibited anchorage inde-
pendent growth of HPV16 E7 transformed NIH 3T3 cells (Reshkin
et al., 2000).
HPV E7 and chromosomal instability
High-risk HPV oncogene expression in primary human keratino-
cytes causes cellular immortalization, and these cells exhibit many of
the hallmarks of premalignant lesions. However, these cells are not
fully transformed, as they do not form tumors when injected into
nude mice. Malignant progression of these cells occurs after
prolonged passaging in culture or when additional oncogenes, such
as ras or fos, are expressed (DiPaolo et al., 1989; Durst et al., 1989;
Hurlin et al., 1991; Pei et al., 1993). Similarly, the development of
cervical cancer in HPV16 E6 and E7 transgenic mice is dependent on
long-term estrogen exposure (Arbeit et al., 1996). This is comparable
to the extended period of time between initial HPV infection and the
development of invasive cervical carcinoma (reviewed in Schiffman
et al., 2007).
Thus, while the expression of the HPV oncogenes is necessary and
sufﬁcient for the initiation of cervical carcinogenesis, additional host
genome mutations are needed for malignant progression. Indeed,
cervical cancer cells have accumulated a wide range of numerical and
structural chromosomal abnormalities (Mitelman et al., 2007) some
of which likely contribute to malignant progression. Gains of
chromosome 3q have been reported to correlate with progression
of severe dysplasia to invasive carcinoma (Heselmeyer et al., 1997,
1996) and transfer of chromosome 11 suppresses the malignant
phenotype of the HPV18-positive HeLa cervical carcinoma cell line
(Rosl et al., 1991; Stanbridge et al., 1982). Development of aneuploidy
is speciﬁcally associated with high-risk, but not low-risk, HPV
infection in vivo (Rihet et al., 1996) and is detected in premalignant
lesions (Bibbo et al., 1989; Steinbeck, 1997) prior to the integration of
HPV genomes into host chromosomes (Bulten et al., 1998; Southern
et al., 1997).
A variety of cytogenetic abnormalities have also been detected in
HPV immortalized keratinocytes (Cottage et al., 2001; Smith et al.,
1989) suggesting that HPV oncogene expression may somehow
facilitate genomic destabilization. This concept was experimentally
provenwhen it was shown that expression of high-risk HPV E6 and/or
E7 in primary human cells increases genomic instability (Hashida and
Yasumoto, 1991; White et al., 1994).
Aneuploidy in HPV E6 and/or E7 expressing cells arises as a
consequence of gains and/or losses of entire chromosomes during
mitosis that can arise as a consequence of multiple types of mitotic
abnormalities including lagging chromosomal material, anaphase
bridges, and multipolar mitoses (Duensing and Munger, 2002).
Abnormal, multipolar mitoses are histopathological hallmarks of
high-risk HPV-associated premalignant lesions and cancers (Winkler
et al., 1984) and are induced by supernumerary centrosomes
(Duensing et al., 2000). The synthesis of centrosomes is intimately
linked to the cell division cycle. After cell division each daughter cell
contains a single centrosomes, which consist of two centrioles. Upon
S-phase entry the two centrioles separate and each centriole then
serve as a template for the synthesis of one daughter centriole. After
completion of S-phase, cells contain two centrosomes that form the
poles of the bipolar mitotic spindle, thus ensuring equal and
symmetric chromosome segregation during cell division (reviewed
in Bettencourt-Dias and Glover, 2007).
High-risk, but not low-risk, HPV E6 and E7 proteins cooperate to
generate mitotic defects and aneuploidy through induction of
340 Minireviewsupernumerary centrosomes and multipolar mitoses in primary
human epithelial cells (Duensing et al., 2000). Supernumerary
centrosomes and associated multipolar mitoses have been detected
in cells that express episomal HPV16 at low copy number (Duensing et
al., 2001b) and their incidence increases in cells with integrated HPV
(Pett et al., 2004; Skyldberg et al., 2001) presumably due to higher E6/
E7 expression. In addition, supernumerary centrosomes have been
documented in HPV16 E6 and/or E7 expressing transgenic mice that
develop cervical (Balsitis et al., 2003; Riley et al., 2003) or skin lesions
(Schaeffer et al., 2004). HPV16 E7 induces supernumerary centro-
somes by uncoupling centriole synthesis from the cell division cycle
causing aberrant centrioles synthesis (Duensing et al., 2001a;
Guarguaglini et al., 2005) through concurrent formation of multiple
daughter centrioles from a single maternal template (Duensing et al.,
2007). Unlike normal centrosome duplication, the ability of HPV16 E7
to induce aberrant centriole synthesis is dependent on cdk2 activity.
The inhibition of cdk2 interferes with E7 mediated induction of
supernumerary centrosomes and decreases the incidence of centro-
some abnormalities and aneuploidy in E7 expressing cells (Duensing
et al., 2006, 2004). As discussed in a previous section, HPV16 E7
expression causes aberrant cdk2 activation through multiple path-
ways. Since HPV16 E7 expression augments the incidence of super-
numerary centrosomes in mouse embryo ﬁbroblasts that lack pRB,
p107 and p130, however, the ability of HPV16 E7 to induce
supernumerary centrosomes is at least in part independent of the
ability to target pRB family members (Duensing and Munger, 2003). A
possible pRB/p107/p130 independent mechanism for the emergence
of supernumerary centrosomes in HPV16 E7 expressing cells involves
the association of E7 with the centrosomal regulator γ-tubulin
through sequences that overlap the pRB core-binding site and
interfere with γ-tubulin recruitment to centrosomes. The association
of HPV16 E7 with γ-tubulin was pRB/p107/p130 independent and
binding correlated with the ability of HPV16 E7 to induce super-
numerary centrosome abnormalities in pRB/p107/p130 deﬁcient cells.
Moreover, HPV16 E7 expression signiﬁcantly inhibited γ-tubulin
recruitment to the centrosome (Nguyen et al., 2007).
Supernumerary centrosomes do not necessarily cause multipolar
mitoses due to a cellular defense mechanism, centrosome coales-
cence, which causes formation of a single mitotic spindle pole by
multiple centrosomes. Such cells undergo pseudo-bipolar mitoses,
although such mitotic events may lead to chromosome segregation
errors. A recent study with high-risk HPV-associated anal carcinomas
has revealed that the vast majority of cells with supernumerary
centrosomes appear to undergo pseudo-bipolar mitosis (Duensing et
al., 2008). Nonetheless, tripolar mitoses are hallmarks of high-risk
HPV-associated lesions and cancers (Crum et al., 1984; Skyldberg et al.,
2001) and a signiﬁcant fraction of HPV16 E6/E7 expressing keratino-
cytes undergo multipolar mitoses (Duensing et al., 2000). In some cell
types, most notably U2OS osteosarcoma cells, E7 expression is
sufﬁcient for the induction of multipolar mitoses, suggesting that
HPV E7 contributes to subversion of centrosome coalescence.
A study from Bill Saunder's group has shown that the nuclear and
mitotic apparatus protein-1 (NuMA) and the microtubule motor
protein dynein play signiﬁcant roles in regulating this process. Oral
cancer cell lines with NuMA overexpression show delocalization of
dynein from the mitotic spindles, which in turn was correlated with
abrogation of centrosome coalescence (Quintyne et al., 2005). HPV16
E7 expression causes dynein delocalization from mitotic spindles
(Nguyen et al., 2008). This activity of E7 maps to a carboxyl terminal
domain that is distinct from the LXCXE sequences that are necessary
for the induction of supernumerary centrosomes. Interestingly,
however, in the context of a normal cell, HPV16 E7 mediated dynein
delocalization is not sufﬁcient to induce induction of multipolar
mitoses (Nguyen et al., 2008). It will be interesting to determine
whether the ability of HPV16 E7 to induce dynein delocalization is
mediated through NuMA and whether it contributes to induction ofmultipolar mitoses in the context of HPV16 E6 expression which has
been shown to greatly increase the incidence of multipolar mitoses in
E7 expressing keratinocytes (Duensing et al., 2000).
HPV16 E7 expression also causes other types of mitotic abnor-
malities including lagging chromosomal material and anaphase
bridges that may represent chromosomal fusions caused by double
stand DNA breaks (Duensing and Munger, 2002). The presence of DNA
repair foci seen in HPV16 E7 expressing cells indicates that E7 may
induce double strand DNA breaks or interfere with break repair. This
may facilitate viral genome integration. Consequently, E7 may be a
driving force for integration of high-risk HPV genomes into host
cellular chromosomes (Kessis et al., 1996), an event that frequently
accompanies malignant progression of high-risk HPV-associated
lesions. Induction of genomic instability and HPV genome integration
may also arise as a direct consequence of HPV genome replication,
through “onion skin” DNA replication, where multiple replication
initiation events occur on a single viral genome template so that
replication is occurring at different stages simultaneously (Kadaja
et al., 2007; Mannik et al., 2002). Thismay result in double stranded
HPV DNA fragments breaking off of the circular genome and being
integrated into the host genome via the endogenous DNA double
strand break (DSB) repair machinery (Kadaja et al., 2007). If the
upstream regulatory region is integrated into the host DNA, it may be
the site of continued “onion skin” replication as long as the viral E1 and
E2 replication proteins are expressed (Kadaja et al., 2007). This
abnormal generation of multiple double stranded DNA fragments
can also initiate DNA DSB repair, which may result in several possible
outcomes: excision of HPV DNA, excision of host DNA, rearrangement
of host or HPV DNA, repeated integration of HPV DNA, or repeated
fragments of host DNA.
Fanconi anemia (FA) patients have an increased incidence of
squamous cell carcinomas at sites that are infected by HPVs (reviewed
in zur Hausen, 2002) and oral cancers arising in FA patients are HPV
positive at a signiﬁcantly higher rate than in the general population
(Kutler et al., 2003). The FA pathway is activated by DNA crosslinking
agents and stalled replication forks (reviewed in Kennedy and
D'Andrea, 2005), and it was recently demonstrated that the FA
pathway is activated by HPV16 E7 expression and that the capacity of
HPV16 E7 to induce DNA repair foci is enhanced in FA patient derived
cell lines (Spardy et al., 2007).
Concluding remarks
At the time this review was written it has been more that 20 years
since the discovery of transforming activity of the HPV16 E7 protein.
Thus one might question (and some grant reviewers do, indeed),
whether or not continued studies on HPV oncoproteins can still yield
conceptually novel insights. Does the fact that one of the authors of
this article (KM) has been studying biological activities and cellular
targets of the HPV E7 proteins for more than 20 years represent
relentless scientiﬁc curiosity or is simply a reﬂection of intellectual
lethargy?While readers of this article might disagree on the answer of
the latter question, these authors would strongly argue that HPV16 E7
will continue to provide a powerful tool to discover novel cellular
signaling pathways that importantly contribute to tumorigenesis.
HPV-associated cancers are unique amongst human solid tumors
since they are uniformly caused by the same carcinogens, expression
of high-risk HPV E6 and E7 oncoproteins. The ﬁndings that HPV16 E7
expression in a transgenic mouse model is sufﬁcient for cervical
cancer development (Riley et al., 2003) and that its continued
expression remains necessary for the maintenance of the transformed
state of cervical cancer derived cells (DeFilippis et al., 2003) clearly
validate the premise that the HPV E7 oncoprotein importantly
contributes to induction and progression of HPV-associated cancers.
Clearly, genome-wide RNA expression analyses as well as novel
proteomic methodologies made it possible to identify novel and
341Minireviewunexpected cellular pathways that HPV16 E7 targets. The ﬁnding that
HPV16 E7 expression induces certain aspects of angiogenesis serves as
a powerful illustration of this point (Chen et al., 2007; Toussaint-Smith
et al., 2004).
With the availability of genome wide libraries of siRNA and cDNA
expression clones, it is now possible to perform loss- and gain-of-
function experiments in mammalian cells that for all practical
purposes approach genetic screens in genetically tractable model
organisms. Such studies, in combination with sophisticated analytical
tools that are developed through the emerging ﬁeld of network
biology, will yield novel and unexpected insights into the molecular
signaling networks that are targeted by HPV E7. We have recently
performed a small-scale, proof-of-principle shRNA screen to investi-
gate whether HPV16 E7 expression alters the kinase requirements of
the RKO colon cancer cell line. These experiments revealed that E7
expression in these cells abrogates the requirement of RKO cells for
CDK6, ERBB3, FYN, AAK1, and TSSK2. The reduced requirement for
CDK6 in E7 expressing RKO cells is not surprising given that HPV16 E7
targets its major phosphorylation substrate, the retinoblastoma tumor
suppressor pRB, for degradation. On the other hand, the biochemical
mechanisms by which E7 expression abrogates the requirement for
the four other kinases in RKO cells are unknown (Baldwin et al., 2008).
Given that kinase signaling pathways are remarkably distinct in
different cell types (Grueneberg et al., 2008), similar studies that are
currently performed in a more appropriate “wild-type” cellular
background promise to reveal exciting new avenues of research.
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